Lower Limb Movement
All ONWARD® Medical therapies are investigational and not available for commercial use.
Discover Our Therapy
Discover Our Therapy
-
ARC Therapy is targeted stimulation of the spinal cord designed to restore movement and other critical functions after spinal cord injury, such as blood pressure stability and bladder control.
These benefits have been observed in published pre-clinical and human feasibility studies.
Watch how it works
Clinical results may vary.
Investigational and not available for commercial use.
Implantable Platform
Implantable Platform
-
Investigational, implantable neurostimulation platform to minimally invasively deliver targeted ARCIM® Therapy to the spinal cord.
The US FDA awarded the ARCIM platform Breakthrough Device Designations for restoration of leg motor function, blood pressure regulation, trunk stabilization, bladder control, and alleviation of spasticity in people with spinal cord injury.
Learn more
We are also advancing brain-computer interface (BCI) technology to restore thought-driven movement after SCI when used with our ARCIM platform.
Read The Evidence
The STIMO study demonstrated the ability of this therapy to enable long-paralyzed people to stand and walk again with little or no assistance.
We received FDA Breakthrough Device Designation for ARCIM in 2020 to restore leg motor function in people with spinal cord injury. Then in 2021, for the use of the system to normalize blood pressure and provide trunk stability, in 2022 for bladder control, and in 2023 for reduced spasticity.
Other potential indications we may explore include improved sexual function and bowel control, and Parkinson’s mobility and gait.
ARCIM + BCI (brain-computer interface)
We are advancing brain-computer interface (BCI) technology to enhance our ARCIM platform with more natural movement after paralysis.
In partnership with EPFL and CEA-Clinatec, in 2021 we successfully implanted an investigational BCI in a human to augment our ARCIM Therapy with thought-driven movement of the legs after paralysis. The approach was published in Nature in May 2023.
With a European Innovation Council grant to study restoration of thought-driven arm and hand movement after SCI, an additional human was implanted with ARCIM Therapy + BCI in 2023. Three more people are scheduled to participate in the study in 2024.
